Biophysical characterization of compounds disrupting the SARS-CoV-2 Spike – ACE2 interaction using SPR
Without rock-solid biophysical predictors of binding affinity and kinetics, the road from molecular screening and simulation to cell-based assays and in vivo testing is virtually unnavigable. Fully characterizing your COVID-19 drug candidate with a proven SPR methodology is the fundament of the successful development of efficacious drugs.
